Welcome to a free weekly resource combining current AI news with peer-reviewed academic papers — curated for professionals working in pharma, market access, health economics, and HTA.
Each issue covers four themed news sections with a plain-English 'So what?' for every story, alongside three recent PubMed papers with lay summaries and direct links to source material.
AI moves faster than peer review. This brief tracks both.
Issue Archive
| Issue | Date | Standout story | Download |
|---|---|---|---|
| Issue 2 | 14 Apr 2026 | Eli Lilly commits $2.75 billion to Insilico Medicine for AI-discovered drug candidates — the first compound advanced from target identification to Phase I in under 30 months, raising urgent questions for HTA bodies evaluating compounds with shorter clinical evidence histories. | Download ↓ |
| Issue 1 (Pilot) |
31 Mar 2026 | Insilico Medicine's ISM001-055 becomes the first AI-designed drug targeting an AI-discovered target to show positive Phase IIa results — over 60% time reduction from project initiation to preclinical candidate. | Download ↓ |
Issue 3 publishes week of 21 April 2026.
Get new issues by email
Free. Weekly. No spam. Unsubscribe any time.
Or follow on LinkedIn — each new issue is also signposted there.
Each issue of the RB Weekly AI Intelligence Brief is automatically generated using AI. Readers are encouraged to verify information via the source links provided in each PDF.